Active ingredientZavegepant HydrochlorideCat. No. P-Z009-001CAS 1414976-20-7Family · Pharmaceutical analytical standards
Zavegepant
A CGRP receptor antagonist (gepant) sprayed into the nose, approved in the United States in March 2023 for the acute treatment of migraine with or without aura in adults. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?The suffix -gepant marks antagonists of the receptor for CGRP, a peptide involved in migraine attacks: zavegepant has been described as the first third-generation gepant given through the nose.
Go to the active ingredient →Active ingredientZavegepant HydrochlorideCat. No. P-Z009-001CAS 1414976-20-7
Isotopically labelledZavegepant-13C-d3Cat. No. P-Z009-002
Impurity1-(1-Methyl-4-piperidinyl)piperazineCat. No. P-Z009-004CAS 23995-88-2
Impurity1-(1-Methylpiperidin-4-yl)piperazine TrihydrochlorideCat. No. P-Z009-005CAS 349535-15-5
Active ingredientZavegepantCat. No. P-Z009-006CAS 1337918-83-8
ImpurityZavegepant Impurity 1Cat. No. P-Z009-007CAS 2923756-41-4
ImpurityZavegepant Impurity 2Cat. No. P-Z009-008No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.